Cargo Therapeutics Insider Receives 25k Stock Options at $4.35

Rhea-AI Filing Summary

SEC Form 4 Filing Overview – Cargo Therapeutics, Inc. (CRGX)

On 20 June 2025, Cargo Therapeutics filed a Form 4 disclosing a routine equity award to board member Krishnan Viswanadhan. On 18 June 2025, the director received a stock-option grant for 25,000 common shares with an exercise price of $4.35 per share and an expiration date of 17 June 2035. The filing records the transaction with code “A,” indicating an award rather than an open-market purchase or sale.

Vesting terms: 100 % of the option vests on the earlier of (i) the one-year anniversary of 18 June 2025 or (ii) the next annual shareholder meeting, provided the director continues to serve. No shares were sold and no cash price was paid at grant (price of derivative security reported as $0), so the transaction is non-cash and non-dilutive at grant, affecting dilution only if the exercise price is paid and shares are issued in the future.

Ownership impact: Following the grant, Viswanadhan beneficially owns 25,000 derivative securities (options) and no change was reported for non-derivative common stock holdings. The filing does not reference any 10b5-1 trading plan, dispositions, or changes in board composition.

Materiality assessment: Director option grants of this size are typical for early-stage biotech boards and do not materially alter the company’s capital structure or near-term cash flow. Consequently, the disclosure is viewed as routine corporate governance information with limited immediate market impact.

Insights

Financial Analyst

TL;DR: Routine 25k option grant to CRGX director; negligible immediate valuation impact.

The Form 4 reports a standard director compensation grant—25,000 options at $4.35, vesting within a year. No shares were bought or sold, so there is no signaling value from insider purchasing or disposal. The award aligns incentives but represents a fraction of Cargo Therapeutics’ fully diluted share count and does not change cash balances. For investors, the filing is primarily a compliance event rather than a catalyst. I classify it as not impactful and assign a neutral (0) rating.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Viswanadhan Krishnan

(Last) (First) (Middle)

C/O CARGO THERAPEUTICS, INC.

835 INDUSTRIAL ROAD, SUITE 400

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CARGO Therapeutics, Inc. [ CRGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.35	06/18/2025		A		25,000		(1)	06/17/2035	Common Stock	25,000	$0	25,000	D

Explanation of Responses:

1. 100% of the shares subject to the option shall vest on the earlier of (i) the one year anniversary of June 18, 2025 or (ii) the next Annual Meeting following June 18, 2025, subject to the Reporting Person's continued service to the Issuer.

	/s/ Halley Gilbert, as attorney-in-fact for Krishnan Viswanadhan	06/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What type of security did CRGX director Krishnan Viswanadhan receive?

A stock-option grant covering 25,000 common shares.

What is the exercise price and term of the CRGX options granted on 18 June 2025?

The options are exercisable at $4.35 per share and expire on 17 June 2035.

When will the 25,000 CRGX options vest?

They vest 100 % on the earlier of 18 June 2026 or the next annual shareholder meeting, subject to continued service.

Did the Form 4 report any sale of Cargo Therapeutics common stock?

No. The filing shows no dispositions; only an option grant coded “A.”

How many derivative securities does Viswanadhan hold after the reported transaction?

He beneficially owns 25,000 stock options following the grant.